Kura Oncology said that it intends to enroll more patients for a registration-directed Phase II trial in 2020 following positive FDA feedback.
The study, presented at the American Society of Hematology meeting, also suggested that a moleculary guided strategy may lead to better outcomes than standard of care.
An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
IMvigor130 data suggests atezolizumab plus chemotherapy delays progression in urothelial carcinoma, with potential survival benefit seen in PD-L1 subgroup treated with monotherapy.
A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.
Based on the strength of the data from the ClarIDHy trial, Agios Pharmaceuticals is aiming to submit for regulatory approval with the FDA by year end.
Men with metastatic castration-resistant prostate cancer who had mutations in genes like BRCA1 and BRCA2 benefited from treatment with olaparib.
Two studies showed that the addition of abemaciclib or ribociclib to fulvestrant improved overall survival in HR-positive, HER2-negative breast cancer patients.
An interim analysis of the IMpower110 study showed that the drug performed better as a first-line treatment than chemotherapy in these patients.
Based on the promising results, the company is advancing the tumor lysate, particle-loaded, dendritic cell vaccine into Phase III studies.